Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin Huls

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
Nature Communications|April 22, 2017
Clonal evolution in myelodysplastic syndromesPedro da Silva-Coelho, Leonie I Kroeze, Kenichi Yoshida, et al.
The New England Journal of Medicine|December 12, 2013
A dominant-negative GFI1B mutation in the gray platelet syndromeDavide Monteferrario, Nikhita A Bolar, Anna E Marneth, et al.
Blood|May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michal Kicinski, Corneel Coens, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Blood|August 19, 2022
Dietary methionine starvation impairs acute myeloid leukemia progressionAlan Cunningham, Ayşegül Erdem, Islam Alshamleh, et al.
BMJ Oncology|January 31, 2025
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?Z L Rana Kaplan, Nikki van Leeuwen, David van Klaveren, et al.
British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Successful Transfer of Umbilical Cord Blood CD34<sup>+</sup> Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia PatientsHarry Dolstra, Mieke W H Roeven, Jan Spanholtz, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Haematologica|July 21, 2018
The phenotypic spectrum of germline <i>YARS2</i> variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2Lisa G Riley, Matthew M Heeney, Joëlle Rudinger-Thirion, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
Nature Communications|April 22, 2017
Clonal evolution in myelodysplastic syndromesPedro da Silva-Coelho, Leonie I Kroeze, Kenichi Yoshida, et al.
The New England Journal of Medicine|December 12, 2013
A dominant-negative GFI1B mutation in the gray platelet syndromeDavide Monteferrario, Nikhita A Bolar, Anna E Marneth, et al.
Blood|May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michal Kicinski, Corneel Coens, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Blood|August 19, 2022
Dietary methionine starvation impairs acute myeloid leukemia progressionAlan Cunningham, Ayşegül Erdem, Islam Alshamleh, et al.
BMJ Oncology|January 31, 2025
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?Z L Rana Kaplan, Nikki van Leeuwen, David van Klaveren, et al.
British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Successful Transfer of Umbilical Cord Blood CD34<sup>+</sup> Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia PatientsHarry Dolstra, Mieke W H Roeven, Jan Spanholtz, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Haematologica|July 21, 2018
The phenotypic spectrum of germline <i>YARS2</i> variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2Lisa G Riley, Matthew M Heeney, Joëlle Rudinger-Thirion, et al.
Pageof 17